Meloxicam Laropharm

Meloxicam, the active ingredient in Meloxicam Laropharm, is a nonsteroidal anti-inflammatory drug (NSAID) presented as a tablet for oral use. It is indicated for the management of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute pain in adult patients. GNH USA supplies Meloxicam Laropharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is an NSAID that reduces inflammation and pain across several musculoskeletal disorders.

Osteoarthritis: alleviates joint pain and improves functional ability. Rheumatoid arthritis: decreases synovial inflammation and slows disease progression. Ankylosing spondylitis: reduces spinal pain and stiffness. Acute pain: provides rapid relief of moderate to severe pain.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Gastrointestinal upset (nausea, dyspepsia) - Abdominal pain - Diarrhea - Headache - Dizziness - Mild skin rash

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding - Cardiovascular events (myocardial infarction, stroke) - Elevated liver enzymes or hepatitis - Severe skin reactions (Stevens‑Johnson syndrome) - Renal impairment or failure - Anaphylaxis or severe hypersensitivity

Before initiating therapy, clinicians should consider several safety aspects.

Assess renal function: evaluate kidney status and adjust use accordingly. Monitor gastrointestinal risk: avoid in patients with active ulcer disease. Use lowest effective dose: limit exposure to reduce adverse events. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Review concomitant NSAIDs or anticoagulants: increased bleeding risk. Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Meloxicam can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased risk of serious bleeding. - ACE inhibitors or ARBs: may reduce renal function. - Lithium: elevated serum lithium levels.

Moderate Interactions (Monitor Closely): - SSRIs: additive bleeding risk. - Diuretics: potential electrolyte disturbances.